Abstract:A previous study found that adding cisplatin, fluorouracil, and docetaxel (TPF) induction chemotherapy to concurrent chemoradiotherapy could improve failure-free survival in patients with locoregionally advanced nasopharyngeal carcinoma (NCT01245959). Paclitaxel liposome may have fewer side effects and work better than paclitaxel. Nedaplatin, a cisplatin analog, has been developed to decrease the toxicities induced by cisplatin, such as nephrotoxicity and gastrointestinal toxicity. In this study, we aimed to evaluate the safety and efficacy of induction chemotherapy with paclitaxel liposome, nedaplatin, and fluorouracil in patients with locally advanced nasopharyngeal carcinoma. In total we included 46 patients with newly diagnosed and pathologically confirmed stage III-IV nonkeratinized nasopharyngeal carcinoma in Nanjing University affiliated Drum Tower Hospital from 2015 May to 2017 June. Patients were treated with paclitaxel Liposome (135mg/m2), nedaplatin (60mg/m2), and fluorouracil (600mg/m2/day×5days), every 3 weeks for 2 cycles. If patients achieved partial response (PR) or complete response (CR) according to the RECIST criteria 1.0, another cycle was then added. Radiotherapy plus concurrent chemotherapy with nedaplatin was subsequently given with a total dose of 70Gy-74Gy with 2Gy per fraction in 35-37 fractions. Treatment response was evaluated 1 month after the end of the treatment. If patients achieved PR or CR, the treatment was consequently ended. The median age of studied patients was 50 years old (range, 25-74 years). Twenty-eight patients (60.9%, 28/46) had stage III disease, nine (19.6%, 9/46) had stage IVa disease and nine patients (19.6%, 9/46) were with stage IVb disease. Thirty-eight patients completed 3 cycles induction chemotherapy (80.1%, 38/47). CTCAE version 4.0 was referred to grade treatment-related toxicities. Three patients (6.5%, 3/46) developed grade 3 bone marrow suppression. Grade 1 nausea occurred in 3 patients (6.5%, 3/46) and grade 1 malaise occurred in 5 patients (10.9%, 5/46). After the induction chemotherapy, no patients achieved CR, 37 patients (80.4%, 37/46) achieved PR, 8 patients (17.4%, 8/46) were with stable disease (SD) and 2 patients (4.3%, 2/46) developed progressive disease (PD) (PR in primary tumor but with lung metastases). After induction chemotherapy plus concurrent chemoradiotherapy, all the patients achieved PR or CR. The median follow-up was 16 months (range, 8-33 months). Distant metastases occurred in 9 patients (5 patients with lung metastasis, 2 with bone metastasis, 2 with liver metastasis), and only 1 patient had in-field recurrence. Induction chemotherapy with paclitaxel liposome, nedaplatin, and fluorouracil is safe and efficient for patients locally advanced nasopharyngeal carcinoma. This regimen is well tolerated and might be especially helpful for patients with poor performance status. The long-term survival will be updated in future.

A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study

A Phase Ii Study of Weekly Nanoparticle Albumin-Bound Paclitaxel Combined with Cisplatin in Patients with Metastatic Breast Cancer

Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial.

Low-dose Nab-Paclitaxel-based Combination Chemotherapy in Heavily-Pretreated Pancreatic or Ampullary Cancer Patients: Taiwanese Single-Center Case Series.

A Retrospective Study in Chinese Patients: is There a Role of Nanoparticle Albumin Bound Paclitaxel in Advanced NSCLC?

A Phase II Study of Weekly Nab-Paclitaxel in Combination with Gemcitabine in Patients with Metastatic Breast Cancer.

Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence

Assessing the Clinical Outcome of Nab-Paclitaxel in Chinese Patients with Advanced Non-Small-cell Lung Cancer.

Induction Chemotherapy with Paclitaxel Liposome, Nedaplatin, and Fluorouracil in Patients with Locally Advanced Nasopharyngeal Carcinoma: A Phase II Study

Evaluating the clinical efficacy and safety of concurrent chemoradiotherapy with cisplatin and nab-paclitaxel in postoperative early-stage cervical cancer

Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel Plus Carboplatin As Neoadjuvant Chemotherapy for Women with Unresectable Ovarian Cancer: a Single-Center, Open Phase IB/II Clinical Trial

Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer

A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus

Expression of Cyclin D1 and Bcl-2 in Infiltrative Ductal Carcinoma of the Breast – Their Correlations and Clinical Implications

Efficacy of gemcitabine in combination with nanoparticle albumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review

Efficacy and safety of concurrent chemoradiotherapy with carboplatin and nanoparticle albumin-bound paclitaxel.

A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer.

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.